Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis

References

• Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223–236. doi:10.1159/000078612.
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332–336. doi:10.1136/bjo.80.4.332.
   PubMed Web of Science ®Google Scholar
• Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology. 2004;111(3):491–500. discussion 500. doi:10.1016/j.ophtha.2003.06.014.
   PubMed Web of Science ®Google Scholar
• Jabs DA. Immunosuppression for the Uveitides. Ophthalmology. 2018;125(2):193–202. doi:10.1016/j.ophtha.2017.08.007.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Daniel E, Dunn JP, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480. http://www.ncbi.nlm.nih.gov/pubmed/19578087.
   PubMedGoogle Scholar
• Kaçmaz RO, Kempen JH, Newcomb C. et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology. 2010;117:576–584. doi:10.1016/j.ophtha.2009.08.010.
   PubMed Web of Science ®Google Scholar
• Gangaputra S, Newcomb CW, Liesegang TL. et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116:2188–2199. doi:10.1016/j.ophtha.2009.04.020.
   PubMed Web of Science ®Google Scholar
• Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology. 2001;108:1134–1139. doi:10.1016/S0161-6420(01)00576-0.
   PubMed Web of Science ®Google Scholar
• Galor A, Jabs DA, Leder HA. et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology. 2008;115:1826–1832. doi:10.1016/j.ophtha.2008.04.026.
   PubMed Web of Science ®Google Scholar
• Pasadhika S, Kempen JH, Newcomb CW. et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol. 2009;148:500–509.e2. doi:10.1016/j.ajo.2009.05.008.
   PubMed Web of Science ®Google Scholar
• Baker KB, Spurrier NJ, Watkins AS, Smith JR, Rosenbaum JT. Retention time for corticosteroid-sparing systemic immunosuppressive agents in patients with inflammatory eye disease. Br J Ophthalmol. 2006;90:1481–1485. doi:10.1136/bjo.2006.097998.
   PubMed Web of Science ®Google Scholar
• Kirbach SE, Hayes OACM. The economic burden of uveitis. Arthritis Rheum. 2010;62(Suppl 10):788. doi:10.1002/art.27631.
   Google Scholar
• Kobelt G, Bodaghi B, Richard B, Plesnilla C, Buchholz PBA. Abstracts of the ISPOR (international society for pharmacoeconomics and outcomes research) eleventh annual European congress. November 8–11 2008, Athens, Greece. Value Health 2008;11(6):A335–A362. doi:10.1111/j.1524-4733.2008.00453_1.x.
   PubMedGoogle Scholar
• Adán-Civera AM, Benítez-Del-Castillo JM, Blanco-Alonso R, Pato-Cour E, Sellas-Fernández A, Bañares-Cañizares A. Burden and direct costs of non infectious uveitis in Spain. Reumatol Clin. 12(4):196–200. doi:10.1016/j.reuma.2015.08.004.
   PubMed Web of Science ®Google Scholar
• Thorne JE, Skup M, Tundia N, et al. Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis. Acta Ophthalmol. 2016;94(5):e331–e339.doi:10.1111/aos.12987.
   PubMed Web of Science ®Google Scholar
• Bañares A, Jover JA, Fernández-Gutiérrez B, et al. Patterns of uveitis as a guide in making rheumatologic and immunologic diagnoses. Arthritis Rheum. 1997;40(2):358–370. http://www.ncbi.nlm.nih.gov/pubmed/9041948.
   PubMed Web of Science ®Google Scholar
• Abásolo L, Prieto-García Á, Díaz-Valle D, et al. Influence of baseline demographic and clinical characteristics in the visual outcome of intermediate uveitis: a survival analysis. Br J Ophthalmol. 2016;100(12):1651–1655.doi:10.1136/bjophthalmol-2015-307774.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140(3):509–516. http://www.ncbi.nlm.nih.gov/pubmed/16196117.
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92(4):467–471. doi:10.1016/s0161-6420(85)34001-0.
   PubMed Web of Science ®Google Scholar
• Bellera CA, MacGrogan G, Debled M, de Lara CT, Brouste V, Mathoulin-Pélissier S. Variables with time-varying effects and the Cox model: some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol. 2010;10(1):20. doi:10.1186/1471-2288-10-20.
   PubMedGoogle Scholar
• Concato J, Peduzzi P, Holford TR, Feinstein AR. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol. 1995;48(12):1495–1501. doi:10.1016/0895-4356(95)00510-2.
   PubMed Web of Science ®Google Scholar
• Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48(12):1503–1510. doi:10.1016/0895-4356(95)00048-8.
   PubMed Web of Science ®Google Scholar
• Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol. 1996;49(12):1373–1379. doi:10.1016/S0895-4356(96)00236-3.
   PubMed Web of Science ®Google Scholar
• Acharya NR, Patel S, Homayounfar G, et al. Relapse of Juvenile idiopathic arthritis-associated Uveitis after discontinuation of immunomodulatory therapy. Ocul Immunol Inflamm. February 2018;1–7. doi:10.1080/09273948.2018.1424341.
   PubMed Web of Science ®Google Scholar
• Saboo US, Metzinger JL, Radwan A, et al. Risk factors associated with the relapse of uveitis in patients with juvenile idiopathic arthritis: a preliminary report. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2013;17(5):460–464.doi:10.1016/j.jaapos.2013.06.004.
   Google Scholar
• Kalinina Ayuso V, van de Winkel EL, Rothova A, de Boer JH. Relapse rate of uveitis post-methotrexate treatment in juvenile idiopathic arthritis. Am J Ophthalmol. 2011;151(2):217–222. doi:10.1016/j.ajo.2010.08.021.
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005;32:362–365. http://www.ncbi.nlm.nih.gov/pubmed/15693100.
   PubMed Web of Science ®Google Scholar
• Simonini G, Bracaglia C, Cattalini M, et al. Predictors of relapse after discontinuing systemic treatment in childhood autoimmune chronic uveitis. J Rheumatol. 2017;44(6):822–826.doi:10.3899/jrheum.161336.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161–1164.doi:10.1093/rheumatology/kem101.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Arida A, Panopoulos S, et al. Brief report: drug-free long-term remission in Severe Behçet’s disease following withdrawal of successful anti-tumor necrosis factor treatment. Arthritis Rheumatol (Hoboken, NJ). 2017;69(12):2380–2385.doi:10.1002/art.40235.
   PubMed Web of Science ®Google Scholar
• Kempen JH, Gewaily DY, Newcomb CW. et al. Remission of intermediate uveitis: incidence and predictive factors. Am J Ophthalmol. 2016;164:110–117.e2. doi:10.1016/j.ajo.2015.12.034.
   PubMed Web of Science ®Google Scholar
• Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014;22(2):96–101. doi:10.3109/09273948.2013.812222.
   PubMed Web of Science ®Google Scholar
• Tsirouki T, Dastiridou A, Symeonidis C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16.doi:10.1080/09273948.2016.1196713.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C. et al. Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012;6:5–12. doi:10.2147/BTT.S27343.
   PubMedGoogle Scholar